Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589443 · ClinicalTrials.gov registry record · Phase 1
Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03589443 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 27 participants.
The verdict
NCT03589443, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The overall aim of this feasibility study is to develop new technologies for improved detection of Barrett's neoplasia using the scanning fiber endoscope(SFE) multiplexed imaging system. This study will combine the use of fluorescent-labeled peptides that bind specifically to pre-cancerous mucosa in the esophagus for use as novel imaging agents to guide endoscopic biopsy or endoscopic mucosal resection (EMR). This Phase 1 study will be used to provide early evidence of efficacy for the topical application of a panel of two peptides that bind to molecular targets that are specific for esophageal dysplasia. A panel is needed because cancer in the esophagus is genetically heterogeneous. The study will look at peptide binding in subjects with known or suspected Barrett's esophagus.
Interventions
- DRUG Multiplexed heptapeptides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03589443
The ClinicalTrials.gov registry entry for NCT03589443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multiplexed heptapeptides is the first listed.
NCT03589443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03589443 about?
NCT03589443 is a clinical study titled "Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus". The overall aim of this feasibility study is to develop new technologies for improved detection of Barrett's neoplasia using the scanning fiber endoscope(SFE) multiplexed imaging system. This study will combine the use of fluorescent-labeled peptides that bind specifically to pre-cancerous mucosa in...
What is the current status of trial NCT03589443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-05-10. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03589443?
The interventions under investigation include: Multiplexed heptapeptides (DRUG).
Who is sponsoring clinical trial NCT03589443?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.